Home > Gastroenterology > DDW 2022 > Upper GI > Cannabis users need more sedation medication for gastroscopy

Cannabis users need more sedation medication for gastroscopy

Presented By
Prof. Yasmin Nasser, University of Calgary, Canada
Presented by
Yasmin Nasser University of Calgary
Conference
DDW
Doi
https://doi.org/10.55788/fa0c88f4
Patients who reported using some sort of cannabinoids had a marked higher likelihood of needing higher doses of midazolam or any diphenhydramine while undergoing a diagnostic esophagogastroduodenoscopy (EGD). For those receiving colonoscopies, no significant difference in dosing requirement was established. Endoscopist-directed conscious sedation (EDCS) is widely used for endoscopic procedures such as gastroscopy and colonoscopy. While efficient and cost-effective, EDCS can be limited by failure to achieve sufficient levels of sedation that enable safe endoscopy. “It is important to be able to predict which patients require higher doses of EDCS or are at a high likelihood of sedation failure,” Prof. Yasmin Nasser (University of Calgary, Canada) explained the motivation for the presented study [1]. In light of the rising number of states/countries that legalise some sort of cannabis, with a resulting larger population of users, Prof. Nasser pointed out that...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on